Choreo LLC Reduces Stake in IQVIA Holdings Inc. (NYSE:IQV)

Choreo LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.9% during the fourth quarter, Holdings Channel reports. The fund owned 5,173 shares of the medical research company’s stock after selling 322 shares during the period. Choreo LLC’s holdings in IQVIA were worth $1,021,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the 3rd quarter worth $27,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC bought a new position in shares of IQVIA in the fourth quarter worth about $33,000. Assetmark Inc. grew its stake in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. increased its holdings in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent analyst reports. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Morgan Stanley lowered their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Stock Down 0.9 %

Shares of NYSE IQV opened at $208.13 on Monday. The firm’s 50-day moving average price is $200.67 and its 200-day moving average price is $219.40. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The stock has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Insider Activity

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.